Remove Clinical Trials Remove Cultivation Remove DEA
article thumbnail

NORML Formally Responds to DEA’s Proposed Changes to Marijuana Cultivation Rules

NORML

Under existing regulations, the agency only licenses one facility — the University of Mississippi — to cultivate cannabis for use in FDA-approved clinical trials. To date, however, the DEA has failed to either affirm or reject any of the more than 30 applications it has received.

article thumbnail

ASA offers solution to DOJ research block: Our comments on the DEA’s proposed rules

Americans for Safe Access

On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Court Dismisses Case Demanding DEA to Move Expeditiously to License Cannabis Cultivators

NORML

A federal court on Friday denied a petition for a writ of mandamus that sought to order the US Drug Enforcement Administration to begin licensing private entities that wish to cultivate cannabis. The agency in 2016 first announced its intent to license private entities to grow cannabis for FDA-approved clinical trials.

DEA 105
article thumbnail

Justice Department Urged To Take “Immediate Action” On Marijuana Grow Applications

NORML

” Last year, however, former DEA director Robert Patterson testified to Congress that the agency believed that approving additional applicants would likely violate international anti-drug treaties. Patterson said that DEA could not move forward granting any new applications until the Justice Department clarified the issue. .”

DEA 195
article thumbnail

Scientists Sue DEA as it Drags its Feet and Hampers Cannabis Research

WeedAdvisor

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety.

DEA 111
article thumbnail

NORML “Senate Unanimously Approves Legislation Providing US Attorney General with Greater Say in Cannabis Research Decisions”

Cannabis Law Report

Senate Bill 253: The Cannabidiol and Marihuana Research Expansion Act provides the office of US Attorney General, rather than the US Drug Enforcement Administration, the discretion to license scientists to engage in clinical trials involving the use of cannabis by human subjects. The full text of S. 253 is online here.

article thumbnail

Rhode Island: MMJ BioPharma Cultivation (MMJBC), MMJ international Holdings (MMJIH), and MMJ BioPharma Labs (MMJBL) File Petition Againt DEA For “Writ of Mandamus”

Cannabis Law Report

Attorneys representing a cannabis biopharma conglomerate and federal cannabis cultivation license applicant filed a petition in court today, citing that the Drug Enforcement Agency (DEA) is taking too long to issue a determination for its application. . Breaking Exclusive: Another Cannabis Company Sues the DEA. Read more at.

DEA 52